非酒精性脂肪性肝病患者中的微小RNA:系统综述与荟萃分析
该系统综述与荟萃分析纳入37项miRNA表达谱研究和6项诊断准确性研究,采用投票计数法分析循环miRNA表达一致性,并用双变量荟萃分析汇总诊断效能。结果显示miRNA-122和miRNA-192持续上调,miRNA-122区分NAFLD与健康对照的AUC为0.82(95%CI 0.75-0.89),miRNA-34a区分NASH与NAFL的AUC为0.78(95%CI 0.67-0.88)。
要点
- miRNA-122和miRNA-192在NAFLD中持续上调。
- miRNA-122区分NAFLD与健康对照的AUC为0.82(95%CI 0.75-0.89)。
- miRNA-34a区分NASH与NAFL的AUC为0.78(95%CI 0.67-0.88)。
核心结论
- miRNA-34a、miRNA-122和miRNA-192被确定为区分NAFL与NASH的潜在诊断标志物。
- miRNA-122区分NAFLD与健康对照、miRNA-34a区分NASH与NAFL均显示中等诊断准确性。
- miRNA-122在NAFL、NASH和纤维化各场景中均上调。
研究设计与样本
- 系统综述与荟萃分析,最终纳入37项miRNA表达谱研究和6项诊断准确性研究进行定量分析。
- 循环miRNA表达一致性和平均倍数变化采用投票计数策略分析。
- 诊断NAFLD或NASH的敏感性、特异性、阳性及阴性似然比、诊断比值比和曲线下面积(AUC)采用双变量荟萃分析汇总。
- 使用Deeks漏斗图评估发表偏倚。
主要发现
- miRNA-122和miRNA-192显示持续上调。
- miRNA-122在用于区分NAFLD严重程度的每个场景中均上调。
- 血清与肝组织之间miRNA表达的相关性在各研究间不一致。
- miRNA-122区分NAFLD与健康对照的AUC为0.82(95%CI 0.75-0.89)。
- miRNA-34a区分NASH与NAFL的AUC为0.78(95%CI 0.67-0.88)。
关键数值与推荐
- miRNA-122区分NAFLD与健康对照的AUC为0.82(95%CI 0.75-0.89)。
- miRNA-34a区分NASH与NAFL的AUC为0.78(95%CI 0.67-0.88)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 血清与肝组织之间miRNA表达的相关性在各研究间不一致,或甚至相反。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: microRNAs (miRNAs) are deregulated in non-alcoholic fatty liver disease (NAFLD) and have been proposed as useful markers for the diagnosis and stratification of disease severity. We conducted a meta-analysis to identify the potential usefulness of miRNA biomarkers in the diagnosis and stratification of NAFLD severity. METHODS: After a systematic review, circulating miRNA expression consistency and mean fold-changes were analysed using a vote-counting strategy. The sensitivity, specificity, positive and negative likelihood ratios, diagnostic odds ratio and area under the curve (AUC) for the diagnosis of NAFLD or non-alcoholic steatohepatitis (NASH) were pooled using a bivariate meta-analysis. Deeks' funnel plot was used to assess the publication bias. RESULTS: Thirty-seven studies of miRNA expression profiles and six studies of diagnostic accuracy were ultimately included in the quantitative analysis. miRNA-122 and miRNA-192 showed consistent upregulation. miRNA-122 was upregulated in every scenario used to distinguish NAFLD severity. The miRNA expression correlation between the serum and liver tissue was inconsistent across studies. miRNA-122 distinguished NAFLD from healthy controls with an AUC of 0.82 (95% CI 0.75-0.89), and miRNA-34a distinguished non-alcoholic steatohepatitis (NASH) from non-alcoholic fatty liver (NAFL) with an AUC of 0.78 (95% CI 0.67-0.88). CONCLUSION: miRNA-34a, miRNA-122 and miRNA-192 were identified as potential diagnostic markers to segregate NAFL from NASH. Both miRNA-122, in distinguishing NAFLD from healthy controls, and miRNA-34a, in distinguishing NASH from NAFL, showed moderate diagnostic accuracy. miRNA-122 was upregulated in every scenario of NAFL, NASH and fibrosis. LAY SUMMARY: microRNAs are deregulated in non-alcoholic fatty liver disease. The microRNAs, miRNA-34a, miRNA-122 and miRNA-192, were identified as potential biomarkers of non-alcoholic fatty liver and non-alcoholic steatohepatitis, at different stages of disease severity. The correlation between miRNA expression in the serum and in liver tissue was inconsistent, or even inverse.
引用
- Liu CH, Ampuero J, Gil-Gómez A, et al. miRNAs in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis. J Hepatol. 2018. PMID: 30142428. doi:10.1016/j.jhep.2018.08.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。